SecBot SecBot

RPRX

Royalty Pharma plc
Nasdaq· Pharmaceutical Preparations· Inc. X0· CIK 0001802768 Biotech & Drug Discovery
$68.43 −0.88 (−1.28%)
Nov 16 4:00 PM ET · prev $69.31
Market cap
$39.6B
Large cap
Consensus
Buy
93% Buy or better · 14 analysts
Median target
$74.00
+8% · range $66.00–78.00
1 year
+74.7%
from $39.16 · Nov 17
30 days
+12.2%
from $60.96
52-week range
$38.09–70.01
−2% from high · low Dec 9
Avg volume 20D
3.38M
shares / day
Short interest
13.08M
≈2.3% of shares · +1.8%
Days to cover
4.0
at average volume
Insider net
−$34.6M
0 buyers · 4 sellers · since May 6
New fund stakes
3
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 2 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/6 ·Next FDA decision date, Nov 27, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $34.6M.

  • InstitutionsBULLISH

    Q2 2026: 54 added (3 new), 25 trimmed or exited. Largest new: Barrow Hanley Mewhinney & Strauss $15.0M, Panagora Asset Management $13.5M.

  • AnalystsBULLISH

    13 of 14 rate it Buy or better. Median target $74.00 (+8%).

  • Short sellersSTEADY

    Short interest +1.8% to 13.08M shares. 4.0 days to cover, ≈2.3% of shares.

  • TrendUPTREND

    11% above its 50-day average. New closing high $70.01 on Nov 11.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$40.8M
in new stakes
FundMoveSharesValue
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED11,193,657$627.6M
BAILLIE GIFFORD & COTRIM10,015,578$561.6M
NORGES BANKADD5,336,084$299.2M
UBS Group AGADD3,143,347$176.2M
NORDEA INVESTMENT MANAGEMENT ABDOUBLED2,576,772$146.2M
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM2,500,000$140.2M
RENAISSANCE TECHNOLOGIES LLCDOUBLED1,935,800$108.5M
CITADEL ADVISORS LLCTRIM1,354,640$76.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 93% rate it Buy or better
Strong Buy4Buy9Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is inside the target range. Median implies +8%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026Citigroup
MAINTAIN
MAINTAINBuy
Oct 7, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Sep 8, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Aug 7, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Jul 13, 2026TD Cowen
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$34.6M
sold · 4 insiders
DateInsiderTypeValue
Nov 6, 2026
Urist Marshall
EVP, Research & Investments
Nov 6, 2026
CONVERT150,000 sh
Nov 6, 2026
Coyne Terrance P.
EVP & CFO
Nov 6, 2026
CONVERT150,000 sh
Nov 6, 2026
Coyne Terrance P.
EVP & CFO
Nov 6, 2026
CONVERT15,000 sh
Nov 6, 2026
Urist Marshall
EVP, Research & Investments
Nov 6, 2026
CONVERT15,000 sh
Nov 6, 2026
Coyne Terrance P.
EVP & CFO
Nov 6, 2026
CONVERT100,000 sh
Nov 6, 2026
Coyne Terrance P.
EVP & CFO
Nov 6, 2026
CONVERT10,000 sh
Nov 4, 2026
Legorreta Pablo G.
CEO, Chairman of the Board
Nov 4, 2026
AWARD42,209 sh
Nov 4, 2026
Urist Marshall
EVP, Research & Investments
Nov 4, 2026
AWARD5,341 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$1.45$1.30–$1.59+12.0%$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
13,075,722
shares short
+1.8%
vs prior settlement
4.0
days to cover
≈2.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

17 filings · 5 press releases · 3 bullish · 1 bearish · 13 neutral
All RPRX filing & press-release reports (22)